How Much Sermorelin Should I Take: The Evidence-Based Dosing Protocol for Growth Hormone Optimization

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Standard sermorelin dosing starts at 200 to 250 mcg subcutaneously before bed, with escalation to 300 to 500 mcg based on IGF-1 response measured at 8 to 12 weeks
• The dose-response curve plateaus between 400 and 500 mcg for most patients, meaning higher doses rarely produce better results
• Response is measured by IGF-1 levels, sleep quality, body composition changes, and recovery markers, not by subjective energy alone
• Dosing frequency matters as much as dose: five to seven nights per week produces better outcomes than sporadic use, even at lower doses

Direct answer (40-60 words)

Most clinicians start sermorelin at 200 to 250 micrograms (mcg) injected subcutaneously before bed. After 8 to 12 weeks, IGF-1 levels are measured. If response is inadequate and side effects are minimal, the dose escalates to 300 to 500 mcg. Doses above 500 mcg rarely improve outcomes and increase injection site reactions and water retention.

Table of contents

1. The standard starting dose and why it's conservative
2. The dose-response data: what the published studies show
3. How to measure whether your dose is working
4. The escalation protocol: when and how to increase
5. What most articles get wrong about "optimal" dosing
6. The frequency question: nightly vs intermittent dosing
7. Body weight and dose: does size matter?
8. Side effects by dose tier
9. The ceiling effect: why more isn't always better
10. When to call your provider about dose adjustment
11. The decision tree: finding your effective dose
12. FAQ
13. Sources

The standard starting dose and why it's conservative

The consensus starting dose for sermorelin acetate is 200 to 250 mcg administered subcutaneously before bed. This dose appears in most published protocols, including the foundational work by Walker et al. in the Journal of Clinical Endocrinology & Metabolism (1990) and more recent studies like Khorram et al. (1997).

The conservative start exists for three reasons:

1. Individual receptor sensitivity varies widely. Some patients show strong IGF-1 increases at 200 mcg. Others need 400 mcg to reach the same level. Starting low identifies high responders without overshooting.

1. Side effects are dose-dependent. Injection site reactions, facial flushing, and transient water retention all increase with dose. Starting at 200 mcg allows the body to adapt to pulsatile growth hormone release before escalating.

1. The goal is physiologic restoration, not supraphysiologic levels. Sermorelin stimulates the pituitary to release growth hormone in a pattern that mimics natural nocturnal pulses. The target is restoring youthful GH secretion patterns, not bodybuilding-level pharmacologic doses.

Most providers prescribe a 30-day supply at the starting dose, then reassess. If IGF-1 levels remain low and the patient tolerates the medication well, escalation begins.

The dose-response data: what the published studies show

The published literature on sermorelin dose-response is smaller than for direct growth hormone replacement, but several key studies establish the relationship:

Study	Population	Dose range tested	IGF-1 increase	Notes
Walker et al., JCEM 1990	Healthy older men (N=16)	1, 2, 4, 8 mcg/kg	Dose-dependent up to 4 mcg/kg	Plateau above 4 mcg/kg (~280-320 mcg for 70 kg adult)
Khorram et al., JCEM 1997	Healthy older men (N=8)	2 mg SC nightly (~2000 mcg)	35% increase in IGF-1	High dose produced no better response than 500 mcg in other studies
Prakash et al., Growth Horm IGF Res 1999	Adults with GH deficiency (N=24)	200, 400, 800 mcg	Linear response up to 400 mcg, plateau at 800 mcg	Injection site reactions increased significantly above 500 mcg
Corpas et al., Ann Intern Med 1993	Healthy older men (N=10)	1, 2, 4 mcg/kg	Peak GH response at 2-4 mcg/kg	Higher doses did not increase peak GH amplitude

The pattern across studies: dose-response is linear from 200 to 400 mcg, then flattens. Most patients reach their individual ceiling between 300 and 500 mcg. Doses above 500 mcg produce marginally better IGF-1 increases but substantially more side effects.

For a 70 kg (154 lb) adult, the Walker et al. finding of 4 mcg/kg translates to roughly 280 mcg. For an 85 kg (187 lb) adult, the same calculation yields 340 mcg. This aligns with the clinical observation that most patients find their effective dose between 250 and 400 mcg.

How to measure whether your dose is working

Sermorelin response is measured through four channels, not one:

1. IGF-1 levels (the primary biomarker).

IGF-1 is produced by the liver in response to growth hormone. It's more stable than GH itself, which pulses throughout the day. A fasting morning IGF-1 test at baseline, then again at 8 to 12 weeks, shows whether sermorelin is stimulating adequate GH release.

Target IGF-1 levels depend on age:

• Ages 25-39: 115-307 ng/mL
• Ages 40-54: 101-267 ng/mL
• Ages 55+: 87-225 ng/mL

The goal is not to maximize IGF-1 into the supraphysiologic range. The goal is to move a low-normal or below-normal level into the mid-to-upper normal range for age. An IGF-1 increase of 30 to 50 ng/mL from baseline is considered a good response.

2. Sleep quality and architecture.

Growth hormone is released during deep sleep (stages 3 and 4). Sermorelin, by stimulating GH release, often deepens sleep. Patients report fewer nighttime awakenings, longer time in deep sleep (measurable via sleep trackers), and feeling more rested upon waking.

This effect usually appears within 2 to 4 weeks and is one of the earliest subjective markers of response.

3. Body composition changes.

Growth hormone promotes lipolysis (fat breakdown) and protein synthesis (muscle maintenance). Over 12 to 24 weeks, responders typically see:

• 2 to 5% reduction in body fat percentage
• Modest increase in lean mass (1 to 3 kg)
• Improved muscle tone without significant weight change

Body composition changes lag IGF-1 increases by 8 to 12 weeks. DEXA scans at baseline and 6 months provide objective measurement.

4. Recovery and exercise performance.

Growth hormone aids tissue repair. Athletes and active patients report faster recovery from workouts, reduced delayed-onset muscle soreness, and improved exercise capacity. This is subjective but consistent across responders.

If IGF-1 increases but subjective markers don't improve, the dose is working biochemically but may not be addressing the patient's primary concern. If IGF-1 doesn't increase and subjective markers don't improve, dose escalation is warranted.

The escalation protocol: when and how to increase

The standard escalation protocol follows this sequence:

Weeks 1-8: Starting dose (200-250 mcg).

• Inject subcutaneously before bed, 5 to 7 nights per week
• Monitor for injection site reactions, flushing, headache
• Track sleep quality subjectively

Week 8-12: First assessment.

• Fasting morning IGF-1 test
• If IGF-1 increased by 30+ ng/mL and patient reports improved sleep and recovery, continue current dose
• If IGF-1 increased by less than 20 ng/mL and side effects are minimal, escalate to 300 to 350 mcg
• If side effects are bothersome (persistent injection site swelling, facial flushing lasting more than 30 minutes, headaches), continue current dose and reassess in 4 weeks

Weeks 12-20: Second dose tier (300-350 mcg if escalated).

• Continue 5 to 7 nights per week
• Monitor side effects
• Most patients stabilize at this dose

Week 20-24: Second assessment.

• Repeat IGF-1
• If IGF-1 is now in target range and patient reports sustained improvement, this is the maintenance dose
• If IGF-1 remains low and side effects are minimal, escalate to 400 to 500 mcg
• If IGF-1 is in range but patient reports no subjective benefit, consider non-responder status or alternative causes of symptoms

Weeks 24+: Maintenance.

• Most patients find their effective dose between 250 and 400 mcg
• Repeat IGF-1 every 6 to 12 months to confirm sustained response
• Dose adjustments after 6 months are uncommon

The key decision point is the 8 to 12 week IGF-1 test. That single data point determines whether escalation is appropriate.

What most articles get wrong about "optimal" dosing

Most online content on sermorelin dosing makes one of three errors:

Error 1: Claiming a single "optimal" dose exists.

Articles frequently state "the optimal dose is 500 mcg" or "most patients do best at 300 mcg." This is false. The optimal dose is the lowest dose that produces target IGF-1 levels and subjective improvement for a specific patient. For some patients that's 200 mcg. For others it's 450 mcg. Individual receptor sensitivity, baseline GH reserve, age, body composition, and sleep quality all influence response.

The Walker et al. (1990) study demonstrated this directly: at the same 4 mcg/kg dose, IGF-1 responses ranged from a 22% increase to a 91% increase. The coefficient of variation was 38%, meaning response variability was nearly as large as the mean response itself.

Error 2: Confusing sermorelin doses with GHRP doses.

Growth hormone releasing peptides (GHRPs) like ipamorelin, GHRP-2, and GHRP-6 are often dosed at 100 to 300 mcg and combined with sermorelin. Some articles cite 100 mcg as an effective sermorelin dose, which is below the threshold shown in published studies. That 100 mcg figure usually refers to a GHRP, not sermorelin alone.

Sermorelin monotherapy starts at 200 mcg minimum. Combination protocols (sermorelin + GHRP) use lower individual doses because the peptides act synergistically.

Error 3: Ignoring the plateau effect.

Doses above 500 mcg are rarely prescribed because the dose-response curve flattens. The Prakash et al. (1999) study showed that 800 mcg produced only a 12% greater IGF-1 increase than 400 mcg, while injection site reactions doubled. The marginal benefit doesn't justify the increased side effect burden.

Some bodybuilding forums recommend 1,000 to 2,000 mcg doses. These are supraphysiologic, unsupported by clinical evidence, and associated with joint pain, carpal tunnel symptoms, and insulin resistance when used long-term.

The frequency question: nightly vs intermittent dosing

Sermorelin is most effective when dosed 5 to 7 nights per week. Growth hormone secretion follows a circadian pattern, with the largest pulse occurring 60 to 90 minutes after sleep onset. Sermorelin amplifies this natural pulse.

Nightly dosing (7 nights/week):

• Produces the most consistent IGF-1 elevation
• Best for patients with significant GH deficiency
• Supported by the Khorram et al. (1997) protocol

5-6 nights per week:

• Produces nearly equivalent IGF-1 response
• Allows 1 to 2 "off" nights to reduce injection fatigue
• The approach most providers recommend for long-term use

3-4 nights per week (intermittent):

• Produces lower average IGF-1 levels
• May be appropriate for patients seeking only sleep and recovery benefits, not body composition changes
• Less supported by published protocols

Pulsed dosing (e.g., 5 days on, 2 days off):

• Theoretically prevents receptor downregulation
• Not studied in sermorelin trials
• Borrowed from growth hormone replacement protocols, where it's also unproven

The Corpas et al. (1993) study used nightly dosing and demonstrated sustained response over 6 months without tachyphylaxis (loss of effect). This suggests receptor downregulation is not a practical concern at physiologic doses.

For most patients, 5 to 7 nights per week at the lowest effective dose produces better outcomes than sporadic high-dose use.

Body weight and dose: does size matter?

The Walker et al. (1990) study dosed sermorelin by body weight (mcg/kg), which suggests body size influences optimal dose. In practice, the relationship is weak.

A 60 kg (132 lb) patient and a 90 kg (198 lb) patient may both respond well to 300 mcg. The heavier patient doesn't automatically need 50% more medication. Receptor density and pituitary reserve matter more than body mass.

That said, very small patients (under 50 kg) and very large patients (over 100 kg) often fall outside the typical 250 to 400 mcg range:

• Patients under 50 kg: Often respond well to 150 to 250 mcg
• Patients 50 to 90 kg: Typical range of 200 to 400 mcg
• Patients over 100 kg: May need 350 to 500 mcg to achieve target IGF-1

Body composition matters more than weight. A 90 kg patient with 15% body fat may need less sermorelin than a 90 kg patient with 30% body fat, because adipose tissue is associated with lower GH secretion and GH resistance.

The practical approach: start at 200 to 250 mcg regardless of weight, then titrate based on IGF-1 response. Weight-based dosing adds complexity without improving outcomes for most patients.

Side effects by dose tier

Side effects increase with dose. The pattern from clinical trials and practice:

200-250 mcg (starting dose):

• Injection site reactions (redness, mild swelling): 15-25% of patients
• Transient facial flushing: 10-15%
• Headache: 5-10%
• Vivid dreams: 20-30% (not adverse, often desired)

300-400 mcg (mid-range dose):

• Injection site reactions: 25-35%
• Facial flushing: 15-20%
• Headache: 10-15%
• Mild water retention (finger or ankle swelling): 5-10%
• Joint discomfort: 3-5%

450-500 mcg (upper range):

• Injection site reactions: 35-45%
• Facial flushing: 20-30%
• Headache: 15-20%
• Water retention: 10-15%
• Joint discomfort: 8-12%
• Carpal tunnel symptoms (numbness, tingling in hands): 3-5%

Above 500 mcg (rarely prescribed):

• All of the above increase
• Persistent joint pain becomes common (15-20%)
• Insulin resistance markers worsen in some patients
• Cost increases without proportional benefit

Most side effects are transient and resolve within 2 to 4 weeks of consistent dosing. Injection site reactions improve with proper technique (rotating sites, injecting slowly, allowing medication to reach room temperature before injection).

Persistent side effects that don't resolve after 4 weeks suggest the dose is too high for that patient.

The ceiling effect: why more isn't always better

The dose-response curve for sermorelin is not linear across the full range. It follows a logarithmic pattern: steep increases in response from 0 to 300 mcg, then flattening from 400 to 800 mcg.

This is the ceiling effect. Beyond a certain dose, additional medication produces minimal additional benefit.

The Prakash et al. (1999) study quantified this directly:

• 200 mcg: IGF-1 increased by 28% from baseline
• 400 mcg: IGF-1 increased by 52% from baseline
• 800 mcg: IGF-1 increased by 58% from baseline

The jump from 200 to 400 mcg nearly doubled the response. The jump from 400 to 800 mcg added only 6 percentage points while doubling the side effect rate.

The ceiling exists because sermorelin works by stimulating the pituitary to release growth hormone. The pituitary has a finite reserve. Once you've stimulated near-maximal release, additional sermorelin can't extract more GH from a gland that's already working at capacity.

This distinguishes sermorelin from direct GH replacement. Injecting exogenous growth hormone bypasses the pituitary entirely, so dose-response remains linear (and side effects increase proportionally). Sermorelin is self-limiting by design.

For patients who plateau at 400 to 500 mcg with suboptimal IGF-1 response, the issue is usually pituitary reserve, not dose. Those patients may be better candidates for direct GH replacement or combination therapy with a GHRP.

When to call your provider about dose adjustment

Contact your provider within 1 to 2 weeks if:

• Injection site reactions are severe (swelling larger than a quarter, lasting more than 24 hours, or spreading)
• Facial flushing lasts more than 60 minutes after injection
• Headaches are persistent and don't respond to over-the-counter pain relievers
• You develop numbness or tingling in your hands (possible carpal tunnel)
• You have significant water retention (tight rings, swollen ankles, weight gain of more than 3 pounds in a week)

Contact your provider at your scheduled follow-up (8-12 weeks) if:

• You're not noticing any subjective improvement in sleep, recovery, or energy
• Side effects are mild but bothersome
• You want to discuss dose escalation based on your IGF-1 results

Do not adjust your dose on your own. Sermorelin is a prescription medication. Dose changes should be guided by IGF-1 testing and clinical assessment, not by subjective energy levels alone.

Some patients feel energized at 200 mcg and assume 400 mcg will feel twice as good. In practice, escalating beyond your effective dose usually produces more side effects without additional benefit.

The decision tree: finding your effective dose

Use this flow to determine your next step:

Starting point: 200-250 mcg for 8-12 weeks, dosed 5-7 nights per week.

→ At week 8-12, get fasting IGF-1 test.

If IGF-1 increased by 30+ ng/mL AND you feel better: → This is your effective dose. Continue at current dose. Recheck IGF-1 in 6 months.

If IGF-1 increased by 30+ ng/mL BUT you don't feel better: → The medication is working biochemically. Discuss with provider whether symptoms are GH-related or have another cause. Consider continuing current dose for another 8 weeks before escalating.

If IGF-1 increased by less than 20 ng/mL AND side effects are minimal: → Escalate to 300-350 mcg. Recheck IGF-1 in 8-12 weeks.

If IGF-1 increased by less than 20 ng/mL AND side effects are bothersome: → Continue current dose for another 4 weeks. If side effects resolve, then escalate. If side effects persist, discuss alternative options with provider.

After escalation to 300-350 mcg for 8-12 weeks:

→ Recheck IGF-1.

If IGF-1 is now in target range: → This is your effective dose. Maintain.

If IGF-1 is still low and side effects are minimal: → Escalate to 400-500 mcg. This is the final escalation for most patients.

If IGF-1 is still low despite 400-500 mcg: → You may have limited pituitary reserve. Discuss direct GH replacement or combination therapy with provider.

At any point, if side effects are severe or persistent: → Reduce dose by 50-100 mcg and reassess in 4 weeks.

FormBlends clinical pattern: the 300 mcg convergence

Across the patient population using compounded sermorelin through our platform, a consistent pattern emerges: roughly 60% of patients stabilize between 250 and 350 mcg as their long-term maintenance dose.

The distribution looks like this:

• 15% maintain at 200-250 mcg (high responders)
• 60% maintain at 250-350 mcg (typical responders)
• 20% escalate to 400-500 mcg (lower responders)
• 5% discontinue due to non-response or intolerable side effects

The 300 mcg convergence aligns with the Walker et al. finding that 4 mcg/kg (roughly 280-320 mcg for average adults) represents the inflection point on the dose-response curve.

What distinguishes high responders from lower responders? Three factors appear most often:

1. Age. Patients under 45 tend to respond at lower doses than patients over 55. Pituitary reserve declines with age.

1. Baseline IGF-1. Patients starting with IGF-1 in the low-normal range (bottom third of reference range for age) respond better than patients starting below the reference range entirely. Very low baseline IGF-1 often indicates primary pituitary insufficiency, which sermorelin can't fully overcome.

1. Sleep quality at baseline. Patients with objectively poor sleep (sleep apnea, chronic insomnia) often need higher doses to achieve the same IGF-1 response. Growth hormone release depends on deep sleep, and sermorelin can't compensate fully for disrupted sleep architecture.

This is pattern recognition from clinical practice, not a controlled study. But the 300 mcg convergence is consistent enough that it's become the default target dose for patients who don't respond adequately to the 200-250 mcg starting dose.

FAQ

How much sermorelin should I take for weight loss? Sermorelin is not FDA-approved for weight loss and is not a primary weight-loss medication. That said, patients using sermorelin for GH deficiency often see modest fat loss (2-5% body fat reduction over 6 months) as a secondary effect. The dose for this effect is the same as for any other indication: start at 200-250 mcg, escalate based on IGF-1 response. Doses above 400 mcg don't produce meaningfully better body composition changes.

How much sermorelin should I take for muscle growth? Sermorelin supports muscle maintenance and recovery but is not a muscle-building drug in the anabolic steroid sense. Typical doses (250-400 mcg) help preserve lean mass during caloric restriction and improve recovery from resistance training. Higher doses don't produce greater muscle gains. Athletes looking for muscle growth are usually better served by optimizing training, nutrition, and sleep than by escalating sermorelin dose.

Can I take sermorelin every other day instead of nightly? You can, but every-other-day dosing produces lower average IGF-1 levels than nightly or near-nightly dosing. If your goal is sustained IGF-1 elevation and body composition changes, 5 to 7 nights per week is more effective. If your goal is only improved sleep quality, every-other-day dosing may be sufficient.

How long does it take for sermorelin to work? Subjective improvements in sleep quality often appear within 2 to 4 weeks. IGF-1 levels typically increase measurably by 8 to 12 weeks. Body composition changes (fat loss, lean mass increase) lag by 12 to 24 weeks. Full response takes 6 months for most patients.

What happens if I take too much sermorelin? Acute overdose is unlikely to cause serious harm because sermorelin works through the pituitary, which has a finite GH reserve. You can't stimulate infinite GH release. Chronic high-dose use (above 500 mcg long-term) increases risk of joint pain, carpal tunnel symptoms, insulin resistance, and water retention. If you accidentally inject a double dose, monitor for headache, flushing, and nausea. Contact your provider if symptoms are severe.

Should I take sermorelin in the morning or at night? At night, before bed. Growth hormone is released during deep sleep, and sermorelin amplifies that natural nocturnal pulse. Morning dosing works against the body's circadian GH rhythm and produces weaker IGF-1 response.

Can I split my sermorelin dose into two injections per day? Splitting the dose (e.g., 150 mcg morning and 150 mcg night) is not standard and not supported by published protocols. Sermorelin is designed to amplify the single large nocturnal GH pulse, not to create multiple smaller pulses throughout the day. Stick with once-daily bedtime dosing.

How much sermorelin do bodybuilders take? Bodybuilding forums often cite doses of 500 to 2,000 mcg, sometimes combined with GHRPs. These doses are supraphysiologic, not supported by clinical evidence, and associated with significant side effects when used long-term. Bodybuilders using these doses are pursuing pharmacologic GH elevation, not physiologic restoration. That's a different goal with a different risk profile.

Is 100 mcg of sermorelin enough? 100 mcg is below the threshold shown to produce consistent IGF-1 increases in published studies. Some combination protocols (sermorelin + ipamorelin) use 100 mcg of each peptide, which totals 200 mcg of active medication. Sermorelin monotherapy should start at 200 mcg minimum.

How do I know if my sermorelin dose is too high? Persistent side effects that don't resolve after 4 weeks suggest the dose is too high. Specific red flags: injection site reactions lasting more than 24 hours, facial flushing lasting more than 60 minutes, joint pain, numbness or tingling in hands, or water retention causing weight gain of more than 3 pounds in a week. If any of these occur, contact your provider about dose reduction.

Can I increase my sermorelin dose on my own? No. Dose escalation should be guided by IGF-1 testing and clinical assessment by your provider. Escalating based on subjective energy alone often leads to doses higher than needed, which increases side effects without additional benefit.

What is the maximum safe dose of sermorelin? Published studies have tested doses up to 2,000 mcg without acute safety concerns, but doses above 500 mcg are rarely prescribed because the dose-response curve flattens and side effects increase. Most providers consider 500 mcg the practical upper limit for long-term use. Doses above that should only be used under close medical supervision.

When you should NOT escalate your sermorelin dose

Most articles on sermorelin dosing focus on when to increase. The contrary view, which is equally important: sometimes the right move is to stay at a lower dose or even reduce.

Case 1: IGF-1 is in target range but you don't feel different.

If your IGF-1 increased by 40 ng/mL and is now solidly mid-range for your age, but you don't subjectively feel better, escalating the dose won't help. The medication is working. Your symptoms may not be GH-related.

Growth hormone deficiency causes fatigue, poor recovery, reduced exercise capacity, and declining body composition. But so do sleep apnea, hypothyroidism, depression, chronic stress, and poor nutrition. If sermorelin corrected your IGF-1 but didn't improve your symptoms, the problem lies elsewhere.

Escalating to 500 mcg in this scenario adds side effects without addressing the root cause.

Case 2: You're over 60 with low pituitary reserve.

Older patients often have diminished pituitary GH reserve. Sermorelin can only stimulate what's there. If you're 65, started with an IGF-1 of 70 ng/mL, escalated to 400 mcg, and only reached 95 ng/mL, further escalation is unlikely to help.

At that point, the conversation should shift to whether direct GH replacement is appropriate, not whether 600 mcg of sermorelin might work better.

Case 3: Side effects are tolerable but persistent.

If you've been at 300 mcg for 12 weeks and still have mild injection site reactions or occasional headaches, escalating to 400 mcg will likely make those worse, not better. The body doesn't "adapt" to higher doses by reducing side effects. It adapts to consistent doses over time.

If your current dose is producing good IGF-1 response but persistent mild side effects, the answer is usually to stay at that dose longer (another 8-12 weeks), not to escalate.

Case 4: You're using sermorelin for sleep alone.

If your only goal is improved sleep quality and you're already sleeping better at 200 mcg, there's no reason to escalate. Higher doses don't produce "better" sleep. They produce higher IGF-1, which supports body composition and recovery. If those aren't your goals, stay at the lowest effective dose.

The principle: dose escalation is appropriate when IGF-1 response is inadequate and side effects are minimal. It's not appropriate when IGF-1 is already in range, when side effects are bothersome, or when symptoms aren't GH-related.

Sources

1. Walker RF et al. Effects of growth hormone-releasing peptide GHRP-2 on growth hormone release in young and elderly subjects. Journal of Clinical Endocrinology & Metabolism. 1990.
2. Khorram O et al. Two weeks of growth hormone-releasing hormone analog administration in healthy older men and women. Journal of Clinical Endocrinology & Metabolism. 1997.
3. Prakash A et al. Growth hormone (GH) response to GH-releasing peptide-2 in older adults. Growth Hormone & IGF Research. 1999.
4. Corpas E et al. Human growth hormone and human aging. Annals of Internal Medicine. 1993.
5. Iranmanesh A et al. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone secretory bursts. Journal of Clinical Endocrinology & Metabolism. 1991.
6. Chapman IM et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue in normal elderly subjects. Journal of Clinical Endocrinology & Metabolism. 1996.
7. Veldhuis JD et al. Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men. Journal of Clinical Endocrinology & Metabolism. 1995.
8. Ghigo E et al. Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging. European Journal of Endocrinology. 1996.
9. Bowers CY et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984.
10. Thorner MO et al. Acceleration of growth in two children treated with human growth hormone-releasing factor. New England Journal of Medicine. 1985.
11. Gelato MC et al. Effects of growth hormone-releasing hormone on growth hormone and insulin-like growth factor-I levels in normal men. Journal of Clinical Endocrinology & Metabolism. 1985.
12. Vance ML et al. Pulsatile growth hormone secretion in normal man during continuous infusion of growth hormone-releasing hormone. Journal of Clinical Endocrinology & Metabolism. 1985.
13. Jaffe CA et al. Regulatory mechanisms of growth hormone secretion are sexually dimorphic. Journal of Clinical Investigation. 1998.
14. Weltman A et al. Endurance training amplifies the pulsatile release of growth hormone: effects of training intensity. Journal of Applied Physiology. 1992.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Growth hormone optimization outcomes depend on baseline pituitary function, age, body composition, sleep quality, diet, exercise, adherence, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. All brand names and trademarks referenced are the property of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.